Massachusetts Financial Services Co. MA Increases Stock Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Massachusetts Financial Services Co. MA raised its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 17.9% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 765,692 shares of the specialty pharmaceutical company's stock after acquiring an additional 116,327 shares during the quarter. Massachusetts Financial Services Co. MA owned approximately 2.38% of Collegium Pharmaceutical worth $29,586,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Gladius Capital Management LP bought a new position in shares of Collegium Pharmaceutical during the second quarter valued at approximately $32,000. GAMMA Investing LLC grew its stake in Collegium Pharmaceutical by 124.5% in the third quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company's stock valued at $55,000 after purchasing an additional 792 shares during the last quarter. CWM LLC raised its holdings in Collegium Pharmaceutical by 97.5% in the third quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company's stock worth $58,000 after purchasing an additional 736 shares in the last quarter. nVerses Capital LLC grew its position in shares of Collegium Pharmaceutical by 1,600.0% in the 2nd quarter. nVerses Capital LLC now owns 1,700 shares of the specialty pharmaceutical company's stock worth $55,000 after buying an additional 1,600 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its stake in shares of Collegium Pharmaceutical by 61.2% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 6,196 shares of the specialty pharmaceutical company's stock worth $239,000 after acquiring an additional 2,352 shares in the last quarter.

Insider Buying and Selling

In other Collegium Pharmaceutical news, EVP Thomas B. Smith sold 9,593 shares of the stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $36.62, for a total transaction of $351,295.66. Following the completion of the transaction, the executive vice president now owns 53,816 shares of the company's stock, valued at $1,970,741.92. This trade represents a 15.13 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Shirley R. Kuhlmann sold 19,248 shares of the business's stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $38.30, for a total transaction of $737,198.40. Following the completion of the sale, the executive vice president now directly owns 120,161 shares in the company, valued at $4,602,166.30. This trade represents a 13.81 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 3.98% of the stock is owned by company insiders.

Collegium Pharmaceutical Price Performance

Shares of Collegium Pharmaceutical stock traded up $0.40 during trading hours on Tuesday, reaching $31.19. 457,107 shares of the company's stock were exchanged, compared to its average volume of 446,068. The business has a fifty day moving average of $35.56 and a two-hundred day moving average of $34.68. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43. The company has a market capitalization of $1.01 billion, a P/E ratio of 13.27 and a beta of 0.95. Collegium Pharmaceutical, Inc. has a 1 year low of $25.16 and a 1 year high of $42.29.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. Truist Financial increased their price target on Collegium Pharmaceutical from $40.00 to $42.00 and gave the company a "buy" rating in a research note on Friday, August 9th. Needham & Company LLC reiterated a "hold" rating on shares of Collegium Pharmaceutical in a research note on Friday, August 9th. HC Wainwright boosted their price objective on shares of Collegium Pharmaceutical from $47.00 to $50.00 and gave the company a "buy" rating in a report on Thursday, September 5th. StockNews.com lowered Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, October 23rd. Finally, Piper Sandler reissued a "neutral" rating and issued a $37.00 price objective on shares of Collegium Pharmaceutical in a report on Friday, October 11th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $42.60.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.